je.st
news
Tag: supplemental
Enterprise to Increase Capacity on Aegis Ethane Pipeline; Conducts Supplemental Open Season
2013-10-21 06:06:18| chemicalonline Home Page
Enterprise Products Partners L.P. recently announced an expansion of its wholly owned Aegis Pipeline following strong interest from shippers. Long-term agreements have been executed, which support increasing the size of the Aegis pipeline to 20-inches in diameter
Tags: open
increase
season
capacity
FY 2013-14 Fall Supplemental Budget: City Budget Office Review
2013-10-19 01:44:20| PortlandOnline
PDF Document, 582kbCategory: FY 2013-14 Budget Monitoring Reports
FY 2013-14 Fall Supplemental Budget: Detailed Requests and Responses
2013-10-19 00:44:21| PortlandOnline
PDF Document, 733kbCategory: FY 2013-14 Budget Monitoring Reports
Tags: fall
detailed
budget
requests
Northrop Grumman Air Claw(TM) Receives Federal Aviation Administration Supplemental Type ...
2013-10-02 06:00:00| Industrial Newsroom - All News for Today
HERNDON, Va. — The Federal Aviation Administration (FAA) has issued Northrop Grumman Corporation's (NYSE: NOC) Air Claw™ a multiuse Supplemental Type Certificate (STC). The STC provides Air Claw™ customers with an FAA-certified airborne surveillance and reconnaissance capability.<br /> <br /> Air Claw™ is based on the rugged Quest KODIAK 100, which is a short take off and landing aircraft.<br /> <br /> The Air Claw™ multiuse STC validates the quality of design and ...This story is related to the following:Vision SystemsSearch for suppliers of: Aerial Reconnaissance Systems
Tags: type
air
administration
federal
Vertex Submits Supplemental New Drug Application (sNDA) To U.S. Food And Drug Administration For KALYDECO (ivacaftor) Monotherapy For People With Non-G551D Gating Mutations
2013-10-02 05:50:27| drugdiscoveryonline News Articles
Vertex Pharmaceuticals Incorporated recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of KALYDECOTM (ivacaftor) monotherapy for people with cystic fibrosis (CF) ages 6 and older who have at least one non-G551D gating mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Tags: with
people
food
application
Sites : [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] next »